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Background: Pulmonary rehabilitation is widely advocated for people with chronic obstructive pulmonary
disease (COPD) to improve exercise capacity, symptoms and quality of life, however only a minority of individuals
with COPD are able to participate. Travel and transport are frequently cited as barriers to uptake of centre-based
programs. Other models of pulmonary rehabilitation, including home-based programs, have been proposed in
order to improve access to this important treatment. Previous studies of home-based pulmonary rehabilitation in
COPD have demonstrated improvement in exercise capacity and quality of life, but not all elements of the
program were conducted in the home environment. It is uncertain whether a pulmonary rehabilitation program
delivered in its entirety at home is cost effective and equally capable of producing benefits in exercise capacity,
symptoms and quality of life as a hospital-based program. The aim of this study is to compare the costs and
benefits of home-based and hospital-based pulmonary rehabilitation for people with COPD.
Methods/Design: This randomised, controlled, equivalence trial conducted at two centres will recruit 166
individuals with spirometrically confirmed COPD. Participants will be randomly allocated to hospital-based or
home-based pulmonary rehabilitation. Hospital programs will follow the traditional outpatient model consisting
of twice weekly supervised exercise training and education for eight weeks. Home-based programs will involve
one home visit followed by seven weekly telephone calls, using a motivational interviewing approach to
enhance exercise participation and facilitate self management. The primary outcome is change in 6-minute walk
distance immediately following intervention. Measurements of exercise capacity, physical activity, symptoms and
quality of life will be taken at baseline, immediately following the intervention and at 12 months, by a blinded
assessor. Completion rates will be compared between programs. Direct healthcare costs and indirect (patient-
related) costs will be measured to compare the cost-effectiveness of each program.
Discussion: This trial will identify whether home-based pulmonary rehabilitation can deliver equivalent benefits
to centre-based pulmonary rehabilitation in a cost effective manner. The results of this study will contribute new
knowledge regarding alternative models of pulmonary rehabilitation and will inform pulmonary rehabilitation
guidelines for COPD.
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Chronic obstructive pulmonary disease (COPD) is char-
acterised by exertional dyspnoea, reduced exercise toler-
ance, marked disability and frequent hospitalisation. The
current economic burden of COPD to the health system
is considerable, with the majority of costs attributable to
hospital use [1,2]. International guidelines for managing
COPD include referral to pulmonary rehabilitation [3],
supported by compelling evidence that such programs
deliver improvement in exercise capacity, reduction in
breathlessness and improvement in health-related quality
of life (HRQOL), irrespective of disease severity [4].
Pulmonary rehabilitation is also associated with a reduced
frequency of acute exacerbations and hospital admissions
[5]. Despite the strong evidence of its benefits, the pro-
portion of people with COPD who receive pulmonary
rehabilitation is very small, with estimates from developed
countries suggesting that it is delivered to less than 5%
of those who would benefit each year [6,7]. Of those
people with COPD who are referred to pulmonary
rehabilitation, 8% to 50% will never attend [8,9], while
non-completion rates range from 10% to 32% [10,11].
The practical reasons for this lack of access include a
shortage of programs, particularly in rural and regional
centres, and an insufficient number of qualified health
professionals. Patient-related barriers to attendance have
also been identified, with travel and transport to centre-
based programs being the most common obstacles to
attendance in this disabled group [8,10-16].
In view of these barriers, the current model of a
centre-based pulmonary rehabilitation program is not
addressing the needs of many people with COPD who
would benefit from this intervention. If new models are
not found, uptake of these programs by patients with
COPD will continue to be limited. Home-based, un-
supervised pulmonary rehabilitation has been proposed
as an alternative model which may enhance access and
uptake while containing the rising costs of healthcare
associated with COPD [17-20]. Direct comparison of
home and centre-based pulmonary rehabilitation has been
explored in four studies [17-20]. Home-based programs
were found to be safe, with improvement in exercise toler-
ance and HRQOL and reduced symptoms demonstrated
in both the home and hospital-based groups. However,
only one study was a non-inferiority trial [18] and import-
ant differences between supervised and unsupervised
groups may not have been detected in other studies. Of
greater importance is that no studies of self-monitored
pulmonary rehabilitation have tested an entirely home-
based intervention. In previous studies participants in the
home training groups were required to attend the hospital
for self-management education [17,18] or weekly monitor-
ing [19]. These approaches fail to overcome the transport
and mobility-related barriers to attendance.Population ageing and the increasing health care burden
associated with chronic disease provide an imperative to
allocate our limited resources effectively [21]. The variety
of program models and staffing used for home-based
rehabilitation in COPD suggests that costs could vary
considerably. One home-based program incorporated
frequent home visits from clinicians to supervise exercise
[20], a model which has proved to be more costly than
centre-based rehabilitation in patients with cardiac disease
[22]. Self-monitored exercise programs utilising telephone
follow up have demonstrated clinical effectiveness [18],
but not all components of pulmonary rehabilitation
were delivered at home and no cost comparison to
centre-based programs was undertaken. Analysis of the
costs of delivery is a critical determinant of whether
such a model of care is suitable for implementation in
clinical practice.
Comprehensive economic evaluation includes both costs
to the healthcare service and the patient [23]. In addition,
cost effectiveness analysis incorporates the evaluation of
the impact of an intervention on the patient, to determine
if benefits are accrued beyond standard healthcare gains.
Such gains may be accessed through measurement of
quality-adjusted life years (QALYs) which quantify the
benefit gained due to an intervention by measuring the
change in quality of life over time. In COPD, centre-based
pulmonary rehabilitation (exercise training and education)
has been demonstrated to be cost-effective with im-
provement in QALYs [24,25]. However, no previous
studies have assessed such outcomes for home-based
pulmonary rehabilitation.
There is a need for new models of pulmonary rehabilita-
tion which allow all program components to be delivered
at home, with proven clinical outcomes and low costs.
The aims of this study are to 1) compare completion rates
of a home-based self-monitored pulmonary rehabilitation
program with a hospital-based, outpatient program in
people with COPD; 2) compare the clinical benefits of
home-based pulmonary rehabilitation and hospital-based
pulmonary rehabilitation and 3) compare the costs of
home-based and hospital-based pulmonary rehabilitation.
We hypothesise that the proportion of patients who
complete pulmonary rehabilitation will be greater in the
home-based intervention; the clinical effects on exercise
capacity, symptoms and quality of life will be equivalent
in both models; and the home-based program will be
more cost-effective.Methods
Design
A randomised, controlled, equivalence trial at two tertiary
hospitals (Austin Health and Alfred Health) in Melbourne,
Australia.
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To be eligible for enrolment, participants must be greater
than 40 years of age, with a diagnosis of COPD based
on an FEV1/FVC ratio of < 70% [3] and a smoking history
(current or former) of a minimum of 10 packet years.
Participants will be excluded if they have 1) diagnosis of
asthma, 2) attended a pulmonary rehabilitation program
within the last 2 years, 3) experienced an exacerbation
of COPD within the last four weeks or 4) have other
comorbidities which will prevent participation in an
exercise training program.
Recruitment and randomisation
Potential participants will be identified via attendance
at respiratory medicine clinics at the Austin or Alfred
Hospitals, upon referral to pulmonary rehabilitation at
these sites, or screened from the existing database of the
pulmonary rehabilitation programs at each site. Eligible
participants will be approached by the researchers who
will explain the study and provide participants with
written and verbal information. The Human Research
Ethics Committees of Alfred Health, Austin Health, La
Trobe University and Monash University have approved
this study, and written, informed consent will be obtained
from all participants. Participants will be randomised to
the hospital or the home based group using stratified
block randomisation, with stratification for site (Austin
or Alfred) and disease severity (FEV1 < 50% predicted
versus FEV1 > 50% predicted) [3]. Randomisation will
be undertaken using a computer generated sequence
and allocation will be concealed using sealed, opaque
envelopes. Participants will be allocated to groups after
completion of baseline assessment. The flow of partici-
pants through the study will reflect the recommenda-
tions of the Consolidated Standard of Reporting Trials
(CONSORT) [26].
Interventions
Hospital-based pulmonary rehabilitation program
Participants will undertake a twice weekly, 8-week out-
patient group-based supervised program, with individu-
ally prescribed exercise training and self-management
education, to be undertaken at their site of recruitment.
The program will follow the guidelines for exercise pre-
scription in COPD [27]. This will include 30 minutes of
aerobic exercise at each session, as well as upper and
lower limb strength training, which will be comprised
of both functional tasks and free weight training. The
initial aerobic exercise prescription for walking will be
set at 80% of the speed walked during a 6-minute walk
test (6MWT) and at 60% of the maximal work-rate for
cycling [28] and progressed each week according to
patient symptoms. Resistance training will utilize func-
tional activities such as stair training and sit to standfrom a chair. Participants will be monitored with pulse
oximetry during exercise training. Participants will also
be encouraged to exercise at a moderate intensity at
home an additional three times per week [27] and this
activity will be recorded in a home diary which is
reviewed weekly. Skill-orientated education and training
sessions conducted by members of the multi-disciplinary
team will be provided, with topics consistent with current
recommendations [27,29]. A record of sessions attended
by each participant will be maintained. The delivery of
the pulmonary rehabilitation is standardised across the
two sites following completion of previous collaborative
pulmonary rehabilitation trials [30].Home-based self-monitored pulmonary
rehabilitation program
Exercise training Participants will undertake an aerobic
and strength training program of similar intensity and
duration to the hospital program. The initial walking
speed will be set at 80% of the speed walked during a
6-minute walk test (6MWT). A goal for walking distance
will be set and distance will be recorded using a pedom-
eter [31]. Participants will be encouraged to exercise for
30 minutes, five times per week and to record the comple-
tion of this activity in a home diary. Resistance training for
the arms and legs will utilise daily activities and equipment
that is readily available in the home environment (e.g.
step-ups on an internal or external step, sit to stand
from a standard height chair, water bottles for upper
limb weights). To ensure safety and understanding of
this exercise program, the initial exercise prescription will
be established during a home visit by a physiotherapist.
During this visit, elements of the self-management pro-
gram that cannot be adequately discussed by subsequent
telephone follow up will also be reviewed, including review
of inhaler technique.
Participants will then be contacted by a physiotherapist
each week by telephone for seven weeks to review the
home diary, progress the exercise prescription and
deliver self-management training. Disease specific self
management training and exercise progression will be
achieved using the principles of motivational interviewing
[32,33]. The aims of this training are to advance disease
knowledge, promote problem solving and facilitate health
behaviour change [34]. Structured telephone modules
will be used, with written prompts for the interviewer
to explore and build motivation for change, then move
towards commitment and action [32]. Exercise goals
will be discussed and documented each week in the
home diary. Participants will also be provided with a
menu of topics covering other aspects of self management
that are routinely discussed in a pulmonary rehabilitation
program [29], including recognition and treatment of
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physical activity; managing breathlessness; good nutrition;
smoking cessation; and accessing community supports.
Participants will be encouraged to choose one topic that is
relevant to them for discussion and goal setting each week.
Health goals will be documented in the standardized
home diary. Training in self-management of acute ex-
acerbations is considered a key element of pulmonary
rehabilitation [29] and this topic will be discussed at least
once during the program. Consistent with the principles
of motivational interviewing, collaborative discussions
will be directed toward building the perceived importance
of behaviour change, increasing confidence, identifying
motivations for change and setting specific goals though
emphasis on participants producing their own arguments
for change [32]. The physiotherapists undertaking the in-
tervention will complete formal training in motivational
interviewing and receive followup support from an experi-
enced motivational interviewing practitioner.
At the completion of the 8-week intervention period,
participants of both groups will be encouraged to con-
tinue with their home exercise program according to the
previously outlined frequency and will be instructed to
document their exercise participation in a monthly diary.
Usual practice at both trial sites is to offer participants
the opportunity to be involved in a community-based
maintenance pulmonary rehabilitation program, in line
with national standards [27]. Participants in both groups
will be offered this option and the proportion of partici-
pants that accept and attend will be documented.
Outcome measures
Baseline demographics of age, gender, body mass index
and lung function (spirometry) will be collected. Spirom-
etry will be repeated at 12 months to determine stability
of lung function. Completion rates will be collated at the
end of the intervention period and compared between
the hospital and home-based groups, with an a priori
definition of completion as undertaking a minimum of
70% of planned pulmonary rehabilitation sessions [35].
Clinical measures will be recorded at baseline, imme-
diately following the intervention period (9 weeks) and
at 12 months post completion of the intervention. An
independent assessor, blinded to group allocation, will
undertake the following measurements at each time
point following the intervention period.
1) Functional exercise capacity will be measured using
the 6-minute walk distance (6MWD), which is a
valid measure of exercise capacity in COPD and is
responsive to pulmonary rehabilitation [36]. Two
tests will be conducted on each testing occasion
using a standardised protocol [36], with the greatest
distance recorded.2) Dyspnoea will be measured using the Modified
Medical Research Council Scale [37].
3) Disease-specific HRQOL will be measured using the
self-reported Chronic Respiratory Disease
Questionnaire (CRDQ), a valid and responsive tool
in pulmonary rehabilitation [38]. It is comprised of
20 questions and assesses the domains of dyspnoea,
fatigue, emotional function and mastery according to
a 7-point Likert scale, with a higher score indicating
better HRQOL.
4) A preference-based measure of HRQOL will be
derived from the Short-form 36 (SF-36), a generic
quality of life measure which is validated in COPD
[39]. Responses to SF-36 will be used to classify health
states using the SF-6D, for economic analyses [40].
5) Self efficacy will be measured using the Pulmonary
Rehabilitation Adapted Index of Self-efficacy (PRAISE),
a tool derived from the General Self-efficacy scale [41].
It is composed of 15 statements, each of which is
scored from 1 to 4, with a higher score indicating
greater levels of self efficacy. It is reproducible and
sensitive to change following pulmonary rehabilitation
in individuals with COPD [41].
6) Anxiety and depression will be measured with the
Hospital Anxiety and Depression Scale (HADS).
This questionnaire is designed to detect and
measure the severity of anxiety and depression [42].
It consists of a series of 14 statements, with
responses based on a 4-point Likert scale. The
HADS is self-administered and has demonstrated
responsiveness to pulmonary rehabilitation [43].
A higher score is indicative of greater anxiety
or depression.
7) In a subgroup of participants, physical activity will
be measured objectively using the SenseWear MF
Armband (SWA, Bodymedia, Pittsburgh, USA) for a
period of seven days. The SWA is a tri-axial
accelerometer worn on the back of the left upper
arm. The SWA produces estimates of energy
expenditure and physical activity intensity using a
proprietary algorithm (version 7.0), as well as
measured outputs (step count). This monitor has
been validated for assessment of daily activity [44]
and used to monitor physical activity participation
[45,46] in people with COPD. Variables to be
reported are total wear time, number of steps per
day, total energy expenditure per day, metabolic
equivalents (METs) per day, awake sedentary time
and time spent in moderate and vigorous activities.
Economic evaluation
Economic evaluation will include direct (health system)
and indirect (personal) health care costs related to the
interventions and the 12 month follow up period. Direct
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overheads and staff transportation. Information on the
costs of the intervention will be based on detailed
information on staff inputs by duration, type and re-
source use. Personal costs to individuals will include
transportation, travel time, and impact of the interven-
tion on the economic activities of other household
members. Health system costs will include the costs of
the intervention(s) and the costs associated with the
use of health services, such as visits to the general practi-
tioner, specialist visits, emergency department visits and
hospitalization in the 12 month follow up period.
Participants will be contacted by telephone every
month during the year-long followup period to document
self-reported health care utilization and to encourage
completion of the monthly diary. Out of pocket medical
expenses will be recorded. Hospitalisation data and use
of hospital services will be confirmed by medical record
audit at the end of the trial. Medical and pharmaceutical
resource use will be confirmed directly via Pharmaceutical
Benefits Scheme (PBS) and Medicare Benefits Schedule
(MBS) data. Medical services, government-subsidised
pharmaceuticals and hospitalisation will be valued accord-
ing to costs derived from the MBS, PBS and the Australian
Refined Diagnosis Related Groups. Costs under the two
interventions will be compared to assess the incremental
impact of home-based rehabilitation for health system
and personal costs. Sensitivity analyses will be carried
out using different assumptions about the cost of
travel and other personal healthcare costs in people
with COPD.
To determine an individual’s self-valuation or utility
of health state at a specific point in time, the SF-36 will
be used to classify health states using the SF-6D [40].
This reflects six dimensions of health state including
physical functioning, role limitations, social functioning,
pain, mental health and vitality. Each attribute contains
four to six levels that account for the 18,000 unique health
states captured by the SF-6D. These indices are combined
to provide a single preference utility index. Responses
will be weighted by predetermined values established
from the general population [47], with the highest score
being 1.0 (best health state) and the lowest score being
0.0 (worst health state) [40] using the standard gamble
utility measurement. This score will be converted to
QALYs, which have the ability to simultaneously cap-
ture information about the gains achieved from re-
duced morbidity (quality gains) and reduced mortality
(quantity gains) [23] and have the assumption that the
duration of each status is exactly one half of the time
between two measurement intervals. An incremental
cost-effective ratio will compare the differences in costs
with differences in gains in QALYs between the two
interventions.Analysis
Continuous variables will be examined with repeated
measures analysis of variance and linear mixed models, as
appropriate. The proportion of participants who complete
the program will be compared between groups using a
chi-squared test and the relative risk of non-completion
will be determined. All data will be analysed by intention
to treat. A per-protocol analysis will also be conducted to
reduce the risk of Type 1 error, as recommended in the
CONSORT Extension for reporting of non-inferiority and
equivalence trials [48]. Alpha will be set at 0.05.
Sample size calculations are based on the primary out-
come of change in 6MWD. If there is truly no difference
in the change in 6MWD between home-based and hos-
pital based groups, then 144 participants are required
to be 80% sure that the 95% confidence interval will
exclude a difference in means of more than 25 metres.
We have recently demonstrated that this is the minimal
important difference for 6MWD in our population of
patients with COPD [49]. This assumes a standard de-
viation of the change in 6MWD of 51 metres [50]. On the
basis of our previous trials in pulmonary rehabilitation
[49,50], we expect 15% attrition from the study; we will
therefore randomize a total of 166 participants.
This sample size will also provide appropriate power
for the secondary outcomes:
Completion: Data from our centres indicate that only
66% people who are referred to pulmonary
rehabilitation take up the referral and complete the
centre-based program. Previous studies have
documented very high completion rates for
home-based programs of over 90% [18]. Using a more
conservative estimate of 85% completion, 144 patients
will be required to detect a difference in completion
rates between hospital and home-based groups
(72 in each group).
Dyspnoea: If there is truly no difference in the change
in the dyspnoea domain of the CRQ between home-
based and hospital based groups, then 142 participants
are required to be 80% sure that the 95% confidence
interval will exclude a difference in means of more than
2.5 points. This is the minimal important difference for
the dyspnoea domain of the CRQ [51] and assumes a
standard deviation of the change in CRQ dyspnoea of
5.1 points [50].
Discussion
This research will be the first study comparing both the
clinical effects and cost effectiveness of delivering pul-
monary rehabilitation in the home and hospital settings.
With the substantial morbidity and mortality associated
with COPD [2], and the growing proportion of people
with COPD, there is an increasing need for cost effective
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vital component of both short and long term management
of COPD [3,29]. Currently, the most common method
of delivering pulmonary rehabilitation is a centre-based
approach, which may be accomplished within an out-
patient hospital department, community centre or private
practice [52]. The lack of access to this intervention for a
significant proportion of people with COPD is likely to be
a contributing factor to the patterns of decline in exercise
capacity and increase in symptoms characteristic of this
disease [3]. In comparing the two modes of delivery on
important clinical features and the economic impact to
both the patient and the healthcare system, further infor-
mation on the feasibility of a home-based model of pul-
monary rehabilitation will be obtained.
It has been well documented that the effects of pulmon-
ary rehabilitation, including those conducted via a centre-
based approach, diminish over time, with deterioration in
both exercise capacity and HRQOL within 6 to 12 months
of program completion [53]. One key reason for this
decline may be the difficulty in maintaining regular ex-
ercise routines and adherence over the longer term
[53]. A critical goal of pulmonary rehabilitation is to
both maximize and sustain benefits. It is possible that
undertaking pulmonary rehabilitation within the home
environment may promote more effective integration
of exercise routines into daily life over the longer term.
With greater adherence to exercise, the initial benefits
of pulmonary rehabilitation may be better maintained.
The results of this study will inform guidelines for the
provision of pulmonary rehabilitation in COPD and may
have a significant impact on the delivery of healthcare
to people with COPD. If it is demonstrated that home-
based exercise achieves equivalent clinical outcomes and
is cost effective compared to a hospital-based program,
this increases the options for the provision of this inter-
vention and may assist in overcoming the most frequently
identified barriers to pulmonary rehabilitation.
Trial status
Patient recruitment commenced in October 2011 and
is continuing.
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